Home / Business and Economy / West Pharma Surges: Q2 Revenue Jumps 13%, Full-Year Guidance Raised
West Pharma Surges: Q2 Revenue Jumps 13%, Full-Year Guidance Raised
24 Jul
Summary
- West Pharmaceutical Services reported $872 million in revenue, a 13% organic increase.
- Adjusted earnings per share rose 29% year-over-year to $2.37.
- Full-year revenue guidance was raised to reflect 11% organic growth.
West Pharmaceutical Services (WST) revealed robust second-quarter financial results on July 23, 2026, highlighting significant year-over-year increases in key metrics. The company achieved $872 million in revenue, marking a 13% organic growth. Adjusted earnings per share (EPS) saw a substantial 29% increase, reaching $2.37. This strong performance has led West Pharmaceutical Services to raise its full-year 2026 financial outlook.
The company now anticipates organic revenue growth between 10% and 11%, with projected adjusted EPS ranging from $8.85 to $9.05. The Proprietary Products segment was a significant driver, experiencing 16% organic growth. Within this segment, the Biologics market group demonstrated exceptional performance with a 29% organic increase.
HVP components, now representing 49% of total revenue, also contributed significantly with an 18% organic rise. This growth is attributed to increased demand for biologics, biosimilars, and GLP-1 elastomers. Double-digit growth was observed across all three major geographic regions, with the Asia Pacific region leading at 27% organic growth.
However, the West Vantage segment experienced only 0.8% organic growth, partly due to a cyber incident in early May that mid-single-digit impact on growth. The company also noted potential impacts on reported growth in the second half of the year due to the divestiture of the SmartDose 3.5 ml on-body delivery system. Inflationary pressures remain a management focus.
